FDA’s On­col­o­gy Cen­ter of Ex­cel­lence touts 2018 ac­com­plish­ments

Im­age: Richard Paz­dur. FDA via FLICKR

The FDA’s re­cent­ly cre­at­ed in­ter-cen­ter On­col­o­gy Cen­ter of Ex­cel­lence (OCE) on Mon­day re­leased its first-ever an­nu­al re­port tout­ing its ac­com­plish­ments in 2018.

OCE was launched in 2017 to speed the de­vel­op­ment and re­view of on­col­o­gy prod­ucts across the FDA’s three med­ical prod­uct cen­ters.

“In 2018, we es­tab­lished a core OCE man­age­ment team and con­tin­ued the work be­gun in 2017 of build­ing pro­grams and launch­ing ini­tia­tives to lever­age ex­per­tise across the FDA and oth­er fed­er­al health agen­cies, as well as acad­e­mia, com­mu­ni­ty prac­ti­tion­ers, and in­dus­try, to ad­vance the de­vel­op­ment and reg­u­la­tion of prod­ucts for peo­ple with can­cer,” writes OCE Di­rec­tor Richard Paz­dur.

2018

With its goal of ex­pe­dit­ing the de­vel­op­ment and re­view of on­col­o­gy and hema­tol­ogy prod­ucts, OCE high­lights the num­ber of reg­u­la­to­ry de­ci­sions it made for new and ex­ist­ing prod­ucts in 2018.

These de­ci­sions in­clude the ap­proval of 19 new mol­e­c­u­lar en­ti­ties (NMEs) and orig­i­nal bi­o­log­ics li­cense ap­pli­ca­tions (BLAs), two biosim­i­lars and a pre­mar­ket ap­proval (PMA) for a new com­pan­ion di­ag­nos­tic that tests for a ge­net­ic mu­ta­tion in pa­tients with acute myeloid leukemia.

2018 On­col­o­gy Ap­provals
19 New Mol­e­c­u­lar En­ti­ties (NMEs)/Bi­o­log­ics Li­cense Ap­pli­ca­tions (BLAs) 32 Ef­fi­ca­cy Sup­ple­ments (New In­di­ca­tions) 1 Ef­fi­ca­cy Sup­ple­ment (New Pa­tient Pop­u­la­tion)
2 Ef­fi­ca­cy Sup­ple­ments (Ac­cel­er­at­ed Ap­proval Con­fir­ma­to­ry Study) 2 Biosim­i­lars 9 505(b)(2) Ap­provals
1 Pre­mar­ket Ap­proval (PMA) – (New Com­pan­ion Di­ag­nos­tic) 10 PMAs (Mod­i­fi­ca­tion to Com­pan­ion Di­ag­nos­tic) 1 PMA (Com­bi­na­tion Prod­uct

The re­port points out that 10 of these ap­provals lever­aged one or both of the cen­ter’s pi­lot re­view pro­grams, re­al time on­col­o­gy re­view (RTOR) and as­sess­ment aid (AAid).

The OCE al­so took part in re­view­ing more than 140 ap­pli­ca­tions for the FDA’s ex­pe­dit­ed pro­grams, in­clud­ing fast track, break­through ther­a­py des­ig­na­tion (BTD), re­gen­er­a­tive med­i­cine ad­vanced ther­a­py (RMAT) and break­through de­vice des­ig­na­tion.

OCE 2018 Ex­pe­dit­ed Pro­gram Sub­mis­sions
Ex­pe­dit­ed Pro­gram Grant­ed De­nied With­drawn
Fast Track 35 22 N/A
Break­through Ther­a­py 25 16 10
Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­py 2 4 0
Break­through De­vice Des­ig­na­tion 18 5 4

In 2018, OCE helped de­vel­op 10 guid­ance and one fi­nal guid­ance doc­u­ments cov­er­ing a range of is­sues from clin­i­cal tri­al end­points for can­cer drugs to de­vel­op­ing and la­bel­ing com­pan­ion di­ag­nos­tics for spe­cif­ic on­col­o­gy ther­a­pies. OCE al­so con­vened 18 pub­lic work­shops and 16 ed­u­ca­tion­al sym­posia in 2018.

In­ter­na­tion­al Col­lab­o­ra­tion

Ke Liu

On the in­ter­na­tion­al front, Paz­dur along with OCE Act­ing As­so­ci­ate Di­rec­tor for Cell and Gene Ther­a­py Ke Liu and Act­ing As­sis­tant Com­mis­sion­er for In­ter­na­tion­al Pro­grams Leigh Ver­bois met with reg­u­la­tors, aca­d­e­mics and in­dus­try in Chi­na in Ju­ly 2018.

Leigh Ver­bois

“Dur­ing our vis­its to Bei­jing, Zhengzhou, Suzhou, and Shang­hai, we de­scribed FDA’s ini­tia­tives in ex­pe­dit­ing the de­vel­op­ment of on­col­o­gy prod­ucts, con­veyed the FDA’s ex­pe­ri­ence in ac­cel­er­at­ing the process of bring­ing in­no­v­a­tive ther­a­pies to mar­ket while main­tain­ing high stan­dards of safe­ty and ef­fi­ca­cy,” the re­port states.

OCE al­so holds month­ly on­col­o­gy in­ter­na­tion­al clus­ter meet­ings with its coun­ter­parts at the Eu­ro­pean Med­i­cines Agency, Health Cana­da, Japan’s Phar­ma­ceu­ti­cals and Med­ical De­vices Agency, Switzer­land’s Swissmedic and Aus­tralia’s Ther­a­peu­tic Goods Ad­min­is­tra­tion.


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

A lab technician works during research on coronavirus at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. (Virginia Mayo/AP Images)

End­points News ranks all 28 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

The 28 players now in or close to the clinical race to get a Covid-19 vaccine over the finish line are angling for a piece of a multibillion-dollar market. And being first — or among the leaders — will play a big role in determining just how big a piece.

Endpoints News writer Nicole DeFeudis has posted a snapshot of all the companies, universities and hospital-based groups now racing through the clinic, ranking them according to their place in the pipeline as well as the latest remarks available on timelines. And we’ll keep this lineup updated right through the end of the year, as the checkered flags start to fall, possibly as early as October.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,400+ biopharma pros reading Endpoints daily — and it's free.

Cell and Gene Con­tract Man­u­fac­tur­ers Must Em­brace Dig­i­ti­za­tion

The Cell and Gene Industry is growing at a staggering 30% CAGR and is estimated to reach $14B by 20251. A number of cell, gene and stem cell therapy sponsors currently have novel drug substances and products and many rely on Contract Development Manufacturing Organizations (CDMO) to produce them with adherence to stringent regulatory cGMP conditions. Cell and gene manufacturing for both autologous (one to one) and allogenic (one to many) treatments face difficult issues such as: a complex supply chain, variability on patient and cellular level, cell expansion count and a tight scheduling of lot disposition process. This complexity affects quality, compliance and accountability in the entire vein-to-vein process for critically ill patients.

Stéphane Bancel speaks to President Donald Trump at the White House meeting on March 2 (AP Images)

UP­DAT­ED: Mod­er­na of­fers steep dis­count in US sup­ply deal — but still takes the crown with close to $2.5B in vac­cine con­tracts

The US pre-order for Moderna’s Covid-19 vaccine is in.

Operation Warp Speed is reserving $1.525 billion for 100 million doses of Moderna’s Phase III mRNA candidate, rounding out to about $15 per dose — including $300 million in incentive payments for timely delivery. Given that Moderna has a two-dose regimen, it’s good for vaccinating 50 million people. The US government also has the option to purchase another 400 million doses for a total of $6.6 billion, or $16.5 per dose.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,400+ biopharma pros reading Endpoints daily — and it's free.

Giovanni Caforio, Bristol Myers Squibb CEO (Christopher Goodney/Bloomberg via Getty Images)

Bris­tol My­ers Squibb com­mits $300 mil­lion to com­bat racial dis­par­i­ties and dou­ble num­ber of Black, Lati­no ex­ec­u­tives

After the police killing of George Floyd, a flurry of pharma and biotech companies, executives and investors jumped out to make statements, either expressing support for Black Lives Matter and the protests or condemning systemic racism.

Now, a Big Pharma company is publicly putting some teeth behind those statements. This morning, Bristol Myers Squibb announced they would spend $300 million on a broad effort to reduce racial health disparities, and diversify both their clinical trials and their own executive team and workforce.

Martin Shkreli (AP Images)

Mar­tin Shkre­li's in­fa­mous Dara­prim falls off top 20 most ex­pen­sive drugs list

Martin Shkreli incited a national uproar five years ago when he raised the price of Daraprim by a factor of 56 essentially overnight from $13.50 to $750 per pill. Now that the “Pharma Bro’s” high-priced project has received a generic, it no longer places among the most expensive drugs in the world.

GoodRx is back with the latest update of the top 20 most expensive drugs and Daraprim’s exclusion marks the biggest change. The drug had previously ranked seventh on the list’s last iteration, which came in February before the world went into quarantine. Another of Shkreli’s former companies, Retrophin, saw its Chenodal drug place in the top 10 again.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,400+ biopharma pros reading Endpoints daily — and it's free.

VBL an­nounces pos­i­tive PhI­II da­ta for ovar­i­an can­cer drug; Gene­Cen­tric part­ners with Janssen on blad­der can­cer

VBL Therapeutics announced that it is on track in a Phase III trial of its drug VB-111 (ofranergene obadenovec) to treat platinum-resistant ovarian cancer in combination with paclitaxel.

After conducting its second interim analysis, the independent Data Safety Monitoring Committee (DSMC) recommended that Israel-based VBL continue full steam ahead. The committee looked at unblinded overall survival rate, which is the primary endpoint of the study, dubbed OVAL. The first analysis evaluated CA-125 response.

FDA ac­cepts pri­or­i­ty re­view for Re­gen­eron's evinacum­ab, which could join Pralu­ent in cho­les­terol mar­ket

Almost a year ago to the day, Regeneron announced solid Phase III testing results for evinacumab, a compound that’s designed to lower LDL cholesterol in patients who need treatment beyond a PCSK9 inhibitor. As that anniversary approaches, the biotech is potentially one step closer to putting it on the market.

The FDA has granted priority review and accepted a BLA for evinacumab as a supplement to other lipid-lowering therapies in individuals with homozygous familial hypercholesterolemia, Regeneron announced Wednesday morning. Regeneron’s target action date is next February 11.

Bayer's Marianne De Backer with Endpoints founder John Carroll, Endpoints@JPM20 (Jeff Rumans for Endpoints News)

UP­DAT­ED: Hunt­ing a block­buster, Bay­er forges an $875M-plus M&A deal to ac­quire women’s health biotech

Bayer has dropped $425 million in cash on its latest women’s health bet, bringing a UK biotech and its non-hormonal menopause treatment into the fold.

KaNDy Therapeutics had its roots in GlaxoSmithKline, which spun out several neuroscience drugs into NeRRe Therapeutics back in 2012. Five years later the team created a new biotech to focus solely on NT-814 — which they considered “one of the few true innovations in women’s health in more than two decades.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,400+ biopharma pros reading Endpoints daily — and it's free.

Eisai moves to 200 Metro Blvd. by late 2021 (ON3)

Ei­sai is cre­at­ing a new US cor­po­rate, R&D HQ in Roche’s old Nut­ley, NJ cam­pus

Eight years after Roche pulled up stakes from Nutley, NJ in a major R&D reorganization, Japan’s Eisai is moving its US corporate and research hub into their old campus.

Now the ON3 property, Eisai — a longtime Biogen partner focused on neurodegenerative disorders like Alzheimer’s — will bring together a staff of up to 1,200 employees. And execs are pitching the move to the New Jersey campus as a cultural game-changer.